<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007394</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA/VACSP #1033</org_study_id>
    <nct_id>NCT03007394</nct_id>
  </id_info>
  <brief_title>Lorcaserin in the Treatment of Cocaine Use Disorder</brief_title>
  <official_title>Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of lorcaserin in the
      treatment of cocaine use disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 19-week, multi-center, randomized, Phase 2 clinical study comparing the efficacy of
      lorcaserin (10mg, b.i.d) to matched placebo in the treatment of cocaine use disorder. Up to 3
      weeks will be allowed for the Screening Period and a 13-week treatment phase, with a 3-week
      follow-up period, with scheduled visits during Study weeks 14 and 16.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the proportion of subjects that successfully achieve abstinence from cocaine during the last three weeks of treatment in the &quot;pre-qualified for primary efficacy endpoint&quot; (PPEE) population</measure>
    <time_frame>Treatment weeks 11 - 13</time_frame>
    <description>Self-report data indicating no cocaine use on each day of the 3-week period, at least one benzoylecgonine (BE) assay result for a urine sample collect within the 3-weeks period and BE assay results are negative for all urine samples collected during the 3-week period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint is the proportion of subjects that successfully achieve abstinence from cocaine during the last three weeks of treatment in the subset of the PPEE population who are either Non-Drinkers or who are attempting alcohol abstinence</measure>
    <time_frame>Treatment weeks 11-13</time_frame>
    <description>Self-report data indicating no cocaine use on each day of the 3-week period, at least one benzoylecgonine (BE) assay result for a urine sample collect within the 3-weeks period and BE assay results are negative for all urine samples collected during the 3-week period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg capsule by mouth, twice a day, for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mg placebo capsule, twice a day, for 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Lorcaserin Capsule</description>
    <arm_group_label>Lorcaserin</arm_group_label>
    <other_name>Belviq</other_name>
    <other_name>lorcaserin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>sugar pill to mimic lorcaserin 10mg capsule</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a DSM-5 diagnosis of current cocaine use disorder as verified by the Structured
             Clinical Interview for DSM-5

          -  Is seeking treatment for cocaine use disorder

          -  Is able to understand and provide written informed consent

          -  Has used cocaine on at least 1 day in the last 30 days prior to screening

          -  Has completed all psychological assessments and procedures during the screening period

          -  If female, not pregnant, lactating, unable to conceive OR must agree to use an
             acceptable method of birth control

          -  Has a total body weight greater than 110 pounds and body mass index greater than 20

        Exclusion Criteria:

          -  Contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shwe Gyaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liza Zeinert</last_name>
    <phone>301-443-1138</phone>
    <email>liza.zeinert@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Treatment and Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Anthenelli, MD</last_name>
      <phone>858-534-9458</phone>
      <email>ranthenelli@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Matrix Institute on Addictions</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel George, MPH</last_name>
      <phone>323-933-9186</phone>
      <email>dgeorge@matrixinstitute.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660-2452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadar Oskooilar, MD</last_name>
      <phone>949-752-7910</phone>
      <email>noskooilar@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga M Lapeyra, MD, CCRP</last_name>
      <phone>305-722-8444</phone>
      <phone_ext>2248</phone_ext>
      <email>olapeyra@behavioralclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118-2391</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Devine, PhD</last_name>
      <phone>617-638-7888</phone>
      <email>eric.devine@bmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac, MD</last_name>
      <phone>702-527-7401</phone>
      <email>DrK@kunovacmd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hassman, DO</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>350</phone_ext>
      <email>hhassman@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shishuka Malhotra, MD</last_name>
      <phone>330-493-1118</phone>
      <email>smalhotra@nb.cr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Winhusen, PhD</last_name>
      <phone>513-585-8292</phone>
      <email>winhust@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CODA, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine Use Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

